Cardio Diagnostics Holdings, Inc. announced that it received notification on May 28, 2025, from The Nasdaq Stock Market LLC that it had regained compliance with the minimum bid price requirement. This fulfills Nasdaq Listing Rule 5550(a)(2) for continued listing.
The company achieved compliance after its common stock traded above $1.00 per share from May 13, 2025, through May 27, 2025. This period immediately followed the effectiveness of the company’s 1-for-30 reverse stock split.
Nasdaq determined that Cardio Diagnostics has regained compliance, and the matter is now considered closed. This resolution removes the immediate risk of delisting, which is a positive development for the company's market standing.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.